This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Whitacre, C. M. Articles by Berger, N. A. Search for Related Content PubMed PubMed Citation Articles by Whitacre, C. M. Articles by Berger, N. A.

Factors Affecting Topotecan-induced Programmed Cell Death: Adhesion Protects Cells from Apoptosis and Impairs Cleavage of Poly(ADP-Ribose)Polymerase¹

Department of Medicine and Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106-4937

We have evaluated the influence of anchorage status together with endogenous levels of bcl-2 family members on the ability of the topoisomerase I inhibitor, topotecan (TPT), to induce programmed cell death (PCD) in human colon, breast, lymphoid, and cervical cancer cell lines. As part of this study, we assessed the use of measuring poly(ADP-ribose) polymerase (PARP) cleavage by Western blot, as an index of apoptosis, relative to measuring chromatin condensation by acridine orange analysis. Our results show a strong correlation between both assays, indicating that PARP cleavage is an accurate method to examine PCD. We have encountered a strong association between cell attachment and sensitivity to TPT-induced PCD. Cells growing attached to flasks appear to be relatively more resistant than suspension-growing cells in spite of endogenous bcl-2, bax, or bcl-x levels. Furthermore, we demonstrate that interference with attachment status alters the sensitivity of cells to TPT-induced PCD. Although cell attachment to ProNectin F confers protection against TPT-induced chromatin condensation and cleavage of PARP, cell detachment by poly(2-hydroxyethyl methacrylate) stimulates TPT-induced PCD and PARP cleavage.

¹ These studies were supported by Grants PO1 CA51183, P30 CA43703, and U01 CA63200 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at Department of Medicine, School of Medicine BRB 301A, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4937. Phone: (216) 368-2825; Fax: (216) 368-116.

Received 6/20/96. Accepted 4/ 4/97.

This article has been cited by other articles:

				J. C. Friedland, J. N. Lakins, M. G. Kazanietz, J. Chernoff, D. Boettiger, and V. M. Weaver {alpha}6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-{kappa}B-dependent resistance to apoptosis in 3D mammary acini J. Cell Sci., October 15, 2007; 120(20): 3700 - 3712. [Abstract] [Full Text] [PDF]

				B. Y. Ma, S. A. Mikolajczak, A. Danesh, K. A. Hosiawa, C. M. Cameron, A. Takaori-Kondo, T. Uchiyama, D. J. Kelvin, and A. Ochi The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells Blood, September 15, 2005; 106(6): 2002 - 2010. [Abstract] [Full Text] [PDF]

				S. Cao, F. A. Durrani, and Y. M. Rustum Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts Clin. Cancer Res., April 1, 2004; 10(7): 2561 - 2569. [Abstract] [Full Text] [PDF]

				A. Dowlati, H. M. Lazarus, P. Hartman, J. W. Jacobberger, C. Whitacre, S. L. Gerson, P. Ksenich, B. W. Cooper, P. S. Frisa, M. Gottlieb, et al. Phase I and Correlative Study of Combination Bryostatin 1 and Vincristine in Relapsed B-Cell Malignancies Clin. Cancer Res., December 1, 2003; 9(16): 5929 - 5935. [Abstract] [Full Text] [PDF]

				M. Guzey, S. Kitada, and J. C. Reed Apoptosis Induction by 1{alpha},25-Dihydroxyvitamin D3 in Prostate Cancer Mol. Cancer Ther., July 1, 2002; 1(9): 667 - 677. [Abstract] [Full Text] [PDF]

				C. Avivi-Green, S. Polak-Charcon, Z. Madar, and B. Schwartz Different Molecular Events Account for Butyrate-Induced Apoptosis in Two Human Colon Cancer Cell Lines J. Nutr., July 1, 2002; 132(7): 1812 - 1818. [Abstract] [Full Text] [PDF]

				G. Hopfl, R. H. Wenger, U. Ziegler, T. Stallmach, O. Gardelle, R. Achermann, M. Wergin, B. Kaser-Hotz, H. M. Saunders, K. J. Williams, et al. Rescue of Hypoxia-inducible Factor-1{alpha}-deficient Tumor Growth by Wild-Type Cells Is Independent of Vascular Endothelial Growth Factor Cancer Res., May 1, 2002; 62(10): 2962 - 2970. [Abstract] [Full Text] [PDF]

				A. Chuntharapai, K. Dodge, K. Grimmer, K. Schroeder, S. A. Marsters, H. Koeppen, A. Ashkenazi, and K. J. Kim Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 J. Immunol., April 15, 2001; 166(8): 4891 - 4898. [Abstract] [Full Text] [PDF]

				C. M. Whitacre, D. K. Feyes, T. Satoh, J. Grossmann, J. W. Mulvihill, H. Mukhtar, and N. L. Oleinick Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4 of SW480 Human Colon Cancer Xenografts in Athymic Mice Clin. Cancer Res., May 1, 2000; 6(5): 2021 - 2027. [Abstract] [Full Text]

				C. M. Whitacre, E. Zborowska, J. K. V. Willson, and N. A. Berger Detection of Poly(ADP-ribose) Polymerase Cleavage in Response to Treatment with Topoisomerase I Inhibitors: A Potential Surrogate End Point to Assess Treatment Effectiveness Clin. Cancer Res., March 1, 1999; 5(3): 665 - 672. [Abstract] [Full Text] [PDF]